Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children

NCT00192205

Last updated date
Study Location
Schneider Children's Medical Center of Israel
Petah-Tikva, , , Israel
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-71 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- who are aged at least 6 months and less than 72 months of age at the time of enrolment;

- who have experienced two or more practitioner attended RTIs* in the past 12 months (since birth if less than 12 months old); * RTIs are defined as upper RTIs including (but not limited to) common cold, acute otitis media and lower RTIs including (but not limited to) bronchiolitis, bronchitis and pneumonia.

- whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained;

- who, along with their parent(s)/legal guardian(s), will be available for duration of the trial;

- whose parent(s)/legal guardian(s), can be reached by study staff for the post-vaccination contacts [telephone, clinic or home visit].

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to
contact for evaluation or study visits during the study period;


- with any serious chronic disease (e.g., with signs of cardiac or renal failure or
severe malnutrition), including progressive neurological disease;


- with Down's syndrome or other known cytogenetic disorders;


- with a known or suspected disease of the immune system or those receiving
immunosuppressive therapy, including systemic corticosteroids of a dose equivalent to
(i) 2mg/kg/day or greater of Prednisolone or (ii) equivalent to a total of 20 mg/day
or greater for children who weigh more than 10kg, for more than 14 days duration until
2 weeks after corticosteroids have been discontinued 27;


- who received any blood products, including immunoglobulin, in the period from six
months prior to vaccination through to the conclusion of the study;


- for whom there is intent to administer any other investigational vaccine or agent from
one month prior to enrolment through to the conclusion of the study;


- who have an immunosuppressed or an immunocompromised individual living in the same
household;


- who, at any time prior to entry into this study, received a dose of any influenza
vaccine (commercial or investigational) or is anticipated to receive a non-study
influenza vaccine after enrollment;


- with a documented history of hypersensitivity to egg or egg protein or any other
component of CAIV-T or TIV;


- who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two
weeks prior to enrolment or for which use is anticipated during the study;


- with any medical conditions that in the opinion of the investigator might interfere
with interpretation of the study results;


Note: Pregnancy in any person who has regular contact with the subject is not a
contraindication to the enrolment or ongoing participation of the subject in the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionsCompliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections
NCT00939185
ALL GENDERS
1 Year+
years
MULTIPLE SITES
Respiratory Tract InfectionsA Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
NCT03529773
  1. Mobile, Alabama
  2. Coral Gables, Florida
  3. Orlando, Florida
  4. Stockbridge, Georgia
  5. Honolulu, Hawaii
  6. Saint Louis, Missouri
  7. Binghamton, New York
  8. Endwell, New York
  9. Charlotte, North Carolina
  10. Raleigh, North Carolina
  11. Wilmington, North Carolina
  12. Winston-Salem, North Carolina
  13. Cincinnati, Ohio
  14. Columbus, Ohio
  15. Dayton, Ohio
  16. Oklahoma City, Oklahoma
  17. Dakota Dunes, South Dakota
  18. Austin, Texas
  19. Austin, Texas
  20. Salt Lake City, Utah
  21. Salt Lake City, Utah
  22. South Jordan, Utah
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionsSafety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
NCT00793000
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children
Official Title  ICMJE A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With a History of Recurrent Respiratory Tract Infections Aged 6 Months to Less Than 72 Months
Brief Summary - Trial to compare the efficacy of the liquid formulation of CAIV-T with TIV against culture confirmed influenza illness in children.
Detailed Description
  • The purpose of this study is to compare the efficacy of the liquid formulation of CAIV-T with TIV against culture confirmed influenza illness in children with a history of recurrent RTIs aged at least 6 months and less than 72 months of age.
  • The trial also provides the opportunity to compare the efficacy of CAIV-T with TIV on acute otitis media.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Respiratory Tract Infections
Intervention  ICMJE Biological: CAIV-T or TIV
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 12, 2005)
2200
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE June 2003
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • who are aged at least 6 months and less than 72 months of age at the time of enrolment;
  • who have experienced two or more practitioner attended RTIs* in the past 12 months (since birth if less than 12 months old); * RTIs are defined as upper RTIs including (but not limited to) common cold, acute otitis media and lower RTIs including (but not limited to) bronchiolitis, bronchitis and pneumonia.
  • whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained;
  • who, along with their parent(s)/legal guardian(s), will be available for duration of the trial;
  • whose parent(s)/legal guardian(s), can be reached by study staff for the post-vaccination contacts [telephone, clinic or home visit].

Exclusion Criteria:

  • whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
  • with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;
  • with Down's syndrome or other known cytogenetic disorders;
  • with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids of a dose equivalent to (i) 2mg/kg/day or greater of Prednisolone or (ii) equivalent to a total of 20 mg/day or greater for children who weigh more than 10kg, for more than 14 days duration until 2 weeks after corticosteroids have been discontinued 27;
  • who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
  • for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrolment through to the conclusion of the study;
  • who have an immunosuppressed or an immunocompromised individual living in the same household;
  • who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational) or is anticipated to receive a non-study influenza vaccine after enrollment;
  • with a documented history of hypersensitivity to egg or egg protein or any other component of CAIV-T or TIV;
  • who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to enrolment or for which use is anticipated during the study;
  • with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results;

Note: Pregnancy in any person who has regular contact with the subject is not a contraindication to the enrolment or ongoing participation of the subject in the study.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Months to 71 Months   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Israel,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00192205
Other Study ID Numbers  ICMJE D153-P514
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE MedImmune LLC
Collaborators  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE Not Provided
PRS Account MedImmune LLC
Verification Date October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP